Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma

SIMPLE SUMMARY: The marine drug lurbinectedin revealed an unprecedented efficacy against patient-derived malignant pleural mesothelioma cells, regardless of the histological type and the BAP1 mutation status. By inducing strong DNA damages, it dramatically arrested cell cycle progression and induced...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Anobile, Dario P., Bironzo, Paolo, Picca, Francesca, Lingua, Marcello F., Morena, Deborah, Righi, Luisella, Napoli, Francesca, Papotti, Mauro G., Pittaro, Alessandra, Di Nicolantonio, Federica, Gigliotti, Chiara, Bussolino, Federico, Comunanza, Valentina, Guerrera, Francesco, Sandri, Alberto, Leo, Francesco, Libener, Roberta, Aviles, Pablo, Novello, Silvia, Taulli, Riccardo, Scagliotti, Giorgio V., Riganti, Chiara
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8151304/
https://ncbi.nlm.nih.gov/pubmed/34066159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102332
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares